Cargando…

A Review of Metabolic Targets of Anticancer Nutrients and Nutraceuticals in Pre-Clinical Models of Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) is a subtype of breast cancer that is notoriously aggressive and has poorer outcomes as compared with other breast cancer subtypes. Due to a lack of targeted therapies, TNBC is often treated with chemotherapeutics as opposed to hormone therapy or other targeted t...

Descripción completa

Detalles Bibliográficos
Autores principales: Wiggs, Alleigh, Molina, Sabrina, Sumner, Susan J., Rushing, Blake R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9146055/
https://www.ncbi.nlm.nih.gov/pubmed/35631131
http://dx.doi.org/10.3390/nu14101990
_version_ 1784716466418876416
author Wiggs, Alleigh
Molina, Sabrina
Sumner, Susan J.
Rushing, Blake R.
author_facet Wiggs, Alleigh
Molina, Sabrina
Sumner, Susan J.
Rushing, Blake R.
author_sort Wiggs, Alleigh
collection PubMed
description Triple-negative breast cancer (TNBC) is a subtype of breast cancer that is notoriously aggressive and has poorer outcomes as compared with other breast cancer subtypes. Due to a lack of targeted therapies, TNBC is often treated with chemotherapeutics as opposed to hormone therapy or other targeted therapies available to individuals with estrogen receptor positive (ER+) breast cancers. Because of the lack of treatment options for TNBC, other therapeutic avenues are being explored. Metabolic reprogramming, a hallmark of cancer, provides potential opportunities to target cancer cells more specifically, increasing efficacy and reducing side effects. Nutrients serve a significant role in metabolic processes involved in DNA transcription, protein folding, and function as co-factors in enzyme activity, and may provide novel strategies to target cancer cell metabolism in TNBC. This article reviews studies that have investigated how nutrients/nutraceuticals target metabolic processes in TNBC cells alone or in combination with existing drugs to exert anticancer effects. These agents have been shown to cause perturbations in many metabolic processes related to glucose metabolism, fatty acid metabolism, as well as autophagy and oxidative stress-related metabolism. With this information, we present the potential of nutrients as metabolism-directed anticancer agents and the potential for using these agents alone or in cocktails as a new direction for TNBC therapy.
format Online
Article
Text
id pubmed-9146055
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-91460552022-05-29 A Review of Metabolic Targets of Anticancer Nutrients and Nutraceuticals in Pre-Clinical Models of Triple-Negative Breast Cancer Wiggs, Alleigh Molina, Sabrina Sumner, Susan J. Rushing, Blake R. Nutrients Review Triple-negative breast cancer (TNBC) is a subtype of breast cancer that is notoriously aggressive and has poorer outcomes as compared with other breast cancer subtypes. Due to a lack of targeted therapies, TNBC is often treated with chemotherapeutics as opposed to hormone therapy or other targeted therapies available to individuals with estrogen receptor positive (ER+) breast cancers. Because of the lack of treatment options for TNBC, other therapeutic avenues are being explored. Metabolic reprogramming, a hallmark of cancer, provides potential opportunities to target cancer cells more specifically, increasing efficacy and reducing side effects. Nutrients serve a significant role in metabolic processes involved in DNA transcription, protein folding, and function as co-factors in enzyme activity, and may provide novel strategies to target cancer cell metabolism in TNBC. This article reviews studies that have investigated how nutrients/nutraceuticals target metabolic processes in TNBC cells alone or in combination with existing drugs to exert anticancer effects. These agents have been shown to cause perturbations in many metabolic processes related to glucose metabolism, fatty acid metabolism, as well as autophagy and oxidative stress-related metabolism. With this information, we present the potential of nutrients as metabolism-directed anticancer agents and the potential for using these agents alone or in cocktails as a new direction for TNBC therapy. MDPI 2022-05-10 /pmc/articles/PMC9146055/ /pubmed/35631131 http://dx.doi.org/10.3390/nu14101990 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Wiggs, Alleigh
Molina, Sabrina
Sumner, Susan J.
Rushing, Blake R.
A Review of Metabolic Targets of Anticancer Nutrients and Nutraceuticals in Pre-Clinical Models of Triple-Negative Breast Cancer
title A Review of Metabolic Targets of Anticancer Nutrients and Nutraceuticals in Pre-Clinical Models of Triple-Negative Breast Cancer
title_full A Review of Metabolic Targets of Anticancer Nutrients and Nutraceuticals in Pre-Clinical Models of Triple-Negative Breast Cancer
title_fullStr A Review of Metabolic Targets of Anticancer Nutrients and Nutraceuticals in Pre-Clinical Models of Triple-Negative Breast Cancer
title_full_unstemmed A Review of Metabolic Targets of Anticancer Nutrients and Nutraceuticals in Pre-Clinical Models of Triple-Negative Breast Cancer
title_short A Review of Metabolic Targets of Anticancer Nutrients and Nutraceuticals in Pre-Clinical Models of Triple-Negative Breast Cancer
title_sort review of metabolic targets of anticancer nutrients and nutraceuticals in pre-clinical models of triple-negative breast cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9146055/
https://www.ncbi.nlm.nih.gov/pubmed/35631131
http://dx.doi.org/10.3390/nu14101990
work_keys_str_mv AT wiggsalleigh areviewofmetabolictargetsofanticancernutrientsandnutraceuticalsinpreclinicalmodelsoftriplenegativebreastcancer
AT molinasabrina areviewofmetabolictargetsofanticancernutrientsandnutraceuticalsinpreclinicalmodelsoftriplenegativebreastcancer
AT sumnersusanj areviewofmetabolictargetsofanticancernutrientsandnutraceuticalsinpreclinicalmodelsoftriplenegativebreastcancer
AT rushingblaker areviewofmetabolictargetsofanticancernutrientsandnutraceuticalsinpreclinicalmodelsoftriplenegativebreastcancer
AT wiggsalleigh reviewofmetabolictargetsofanticancernutrientsandnutraceuticalsinpreclinicalmodelsoftriplenegativebreastcancer
AT molinasabrina reviewofmetabolictargetsofanticancernutrientsandnutraceuticalsinpreclinicalmodelsoftriplenegativebreastcancer
AT sumnersusanj reviewofmetabolictargetsofanticancernutrientsandnutraceuticalsinpreclinicalmodelsoftriplenegativebreastcancer
AT rushingblaker reviewofmetabolictargetsofanticancernutrientsandnutraceuticalsinpreclinicalmodelsoftriplenegativebreastcancer